Abstract |
Eleven piperazine-containing 1,3-diphenylprop-2-en-1-one derivatives (PC1-PC11) were evaluated for their inhibitory activities against monoamine oxidases (MAOs), cholinesterases ( ChEs), and β-site amyloid precursor protein cleaving enzyme 1 (BACE-1) with a view toward developing new treatments for neurological disorders. Compounds PC10 and PC11 remarkably inhibited MAO-B with IC50 values of 0.65 and 0.71 μM, respectively. Ten of the eleven compounds weakly inhibited AChE and BChE with > 50% of residual activities at 10 μM, although PC4 inhibited AChE by 56.6% (IC50 = 8.77 μM). Compound PC3 effectively inhibited BACE-1 (IC50 = 6.72 μM), and PC10 and PC11 moderately inhibited BACE-1 (IC50 =14.9 and 15.3 μM, respectively). Reversibility and kinetic studies showed that PC10 and PC11 were reversible and competitive inhibitors of MAO-B with Ki values of 0.63 ± 0.13 and 0.53 ± 0.068 μM, respectively. ADME predictions for lead compounds revealed that PC10 and PC11 have central nervous system (CNS) drug-likeness. Molecular docking simulations showed that fluorine atom and trifluoromethyl group on PC10 and PC11, respectively, interacted with the substrate cavity of the MAO-B active site. Our results suggested that PC10 and PC11 can be considered potential candidates for the treatment of neurological disorders such as Alzheimer's disease and Parkinson's disease.
|
Authors | Bijo Mathew, Jong Min Oh, Roua S Baty, Gaber El-Saber Batiha, Della Grace Thomas Parambi, Nicola Gambacorta, Orazio Nicolotti, Hoon Kim |
Journal | Environmental science and pollution research international
(Environ Sci Pollut Res Int)
Vol. 28
Issue 29
Pg. 38855-38866
(Aug 2021)
ISSN: 1614-7499 [Electronic] Germany |
PMID | 33743158
(Publication Type: Journal Article)
|
Copyright | © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
Chemical References |
- Chalcones
- Cholinesterase Inhibitors
- Monoamine Oxidase Inhibitors
- Piperazine
- Monoamine Oxidase
|
Topics |
- Alzheimer Disease
(drug therapy)
- Chalcones
(pharmacology)
- Cholinesterase Inhibitors
(pharmacology)
- Humans
- Kinetics
- Molecular Docking Simulation
- Monoamine Oxidase
(metabolism)
- Monoamine Oxidase Inhibitors
(pharmacology)
- Piperazine
- Structure-Activity Relationship
|